Supernus Pharmaceuticals
Develops and commercializes treatments for central nervous system disorders.
Company facts
- Founded
- 2005
- Employees
- 674
- Headquarters
- United States
- Type
- Public
- Listed
- NASDAQ: SUPN
- Subsidiaries
- Adamas Pharmaceuticals
About
Supernus Pharmaceuticals, Inc. is an award-winning biopharmaceutical company specializing in the development and commercialization of innovative products targeting central nervous system (CNS) diseases. With over 30 years of industry experience, we have successfully established a portfolio that addresses significant health issues, such as epilepsy, ADHD, and Parkinson's disease. Our mission is to enhance the lives of patients suffering from CNS disorders through our dedicated research and development efforts, which are vital to our success. At Supernus, our pipeline includes a variety of therapeutic candidates addressing large market opportunities in CNS conditions. We have marketed several products within the United States through our own specialized sales force while also pursuing strategic collaborations globally. Our commitment to patient care and innovative science drives us to improve therapies continuously and to bring forward additional treatment options that can drastically change the healthcare landscape for millions.